JP2015507635A5 - - Google Patents

Download PDF

Info

Publication number
JP2015507635A5
JP2015507635A5 JP2014550538A JP2014550538A JP2015507635A5 JP 2015507635 A5 JP2015507635 A5 JP 2015507635A5 JP 2014550538 A JP2014550538 A JP 2014550538A JP 2014550538 A JP2014550538 A JP 2014550538A JP 2015507635 A5 JP2015507635 A5 JP 2015507635A5
Authority
JP
Japan
Prior art keywords
compound according
alkyl
pharmaceutically acceptable
alkylene
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014550538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015507635A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/072283 external-priority patent/WO2013102195A1/en
Publication of JP2015507635A publication Critical patent/JP2015507635A/ja
Publication of JP2015507635A5 publication Critical patent/JP2015507635A5/ja
Pending legal-status Critical Current

Links

JP2014550538A 2011-12-30 2012-12-31 組成物、合成およびフェニルシクロアルキルメチルアミン誘導体を使用する方法 Pending JP2015507635A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161582201P 2011-12-30 2011-12-30
US61/582,201 2011-12-30
PCT/US2012/072283 WO2013102195A1 (en) 2011-12-30 2012-12-31 Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018076091A Division JP2018138566A (ja) 2011-12-30 2018-04-11 組成物、合成およびフェニルシクロアルキルメチルアミン誘導体を使用する方法

Publications (2)

Publication Number Publication Date
JP2015507635A JP2015507635A (ja) 2015-03-12
JP2015507635A5 true JP2015507635A5 (cg-RX-API-DMAC10.html) 2016-01-28

Family

ID=48698693

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014550538A Pending JP2015507635A (ja) 2011-12-30 2012-12-31 組成物、合成およびフェニルシクロアルキルメチルアミン誘導体を使用する方法
JP2018076091A Pending JP2018138566A (ja) 2011-12-30 2018-04-11 組成物、合成およびフェニルシクロアルキルメチルアミン誘導体を使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018076091A Pending JP2018138566A (ja) 2011-12-30 2018-04-11 組成物、合成およびフェニルシクロアルキルメチルアミン誘導体を使用する方法

Country Status (20)

Country Link
US (3) US9238625B2 (cg-RX-API-DMAC10.html)
EP (1) EP2797870B1 (cg-RX-API-DMAC10.html)
JP (2) JP2015507635A (cg-RX-API-DMAC10.html)
KR (1) KR20140110014A (cg-RX-API-DMAC10.html)
CN (1) CN104039753B (cg-RX-API-DMAC10.html)
AU (1) AU2012362105B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014016122A8 (cg-RX-API-DMAC10.html)
CA (1) CA2858837C (cg-RX-API-DMAC10.html)
CO (1) CO7071125A2 (cg-RX-API-DMAC10.html)
ES (1) ES2726807T3 (cg-RX-API-DMAC10.html)
IL (1) IL233083A0 (cg-RX-API-DMAC10.html)
IN (1) IN2014MN01407A (cg-RX-API-DMAC10.html)
MX (1) MX352874B (cg-RX-API-DMAC10.html)
MY (1) MY170643A (cg-RX-API-DMAC10.html)
PH (1) PH12014501313A1 (cg-RX-API-DMAC10.html)
RU (1) RU2642074C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201403165SA (cg-RX-API-DMAC10.html)
UA (1) UA114807C2 (cg-RX-API-DMAC10.html)
WO (1) WO2013102195A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201404711B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN01407A (cg-RX-API-DMAC10.html) 2011-12-30 2015-07-03 Reviva Pharmaceuticals Inc
CA3127453A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof
CA3127590A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
IE56000B1 (en) 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
US5015664A (en) 1984-01-26 1991-05-14 Oral D Orally effective ion chelators related to deferoxamine
GB8501192D0 (en) 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
ZA925185B (en) * 1991-07-18 1993-04-29 Hoffmann La Roche Dithianes.
US5596019A (en) 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
GB9914742D0 (en) 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
GB9914744D0 (en) 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002036540A2 (en) 2000-11-02 2002-05-10 Torrent Pharmaceuticals Ltd PROCESS FOR PREPARATION OF β-PHENETHYLAMINE DERIVATIVE
EE05735B1 (et) 2001-02-24 2015-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
GB0230134D0 (en) 2002-12-24 2003-01-29 Amedis Pharm Ltd Compounds and their use
WO2004096202A1 (en) 2003-04-28 2004-11-11 Cipla Limited Pharmaceutical formulation comprising anti-obesity agent and acidulant
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
WO2007014929A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
US20070203111A1 (en) 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
JP2007254409A (ja) * 2006-03-24 2007-10-04 Taisho Pharmaceut Co Ltd イミダゾリジノン誘導体
KR101441146B1 (ko) 2006-04-28 2014-09-17 시오노기세야쿠 가부시키가이샤 Npy y5 수용체 길항 작용을 갖는 아민 유도체
AU2007296074B2 (en) * 2006-09-15 2012-07-12 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
SA08290668B1 (ar) 2007-10-25 2012-02-12 شيونوجي آند كو.، ليمتد مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها
KR20100092473A (ko) 2007-11-01 2010-08-20 액테리온 파마슈티칼 리미티드 신규한 피리미딘 유도체
CN102405209A (zh) 2009-04-21 2012-04-04 安斯泰来制药株式会社 二酰基乙二胺化合物
US8227618B2 (en) * 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
IN2014MN01407A (cg-RX-API-DMAC10.html) 2011-12-30 2015-07-03 Reviva Pharmaceuticals Inc

Similar Documents

Publication Publication Date Title
ES2989617T3 (es) Moduladores de receptores de quimioquinas y usos de los mismos
AU2017260367B2 (en) Modulators of the integrated stress pathway
Wolfe et al. A chemical proteomics approach to profiling the ATP-binding proteome of Mycobacterium tuberculosis
JP2013032389A5 (cg-RX-API-DMAC10.html)
JP2014511892A5 (cg-RX-API-DMAC10.html)
JP2013523802A5 (cg-RX-API-DMAC10.html)
CA3080808A1 (en) Modulators of the integrated stress pathway
JP2019515042A (ja) 統合ストレス経路のモジュレーター
JP2018500343A5 (cg-RX-API-DMAC10.html)
JP2017527561A5 (cg-RX-API-DMAC10.html)
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
JP2013510120A5 (cg-RX-API-DMAC10.html)
JP2014508753A5 (cg-RX-API-DMAC10.html)
JP2013525356A5 (cg-RX-API-DMAC10.html)
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
EP4282482A3 (en) Nucleoside phosphoramidate prodrugs
AU2014233520A1 (en) Modulators of the eIF2alpha pathway
JP2016512834A5 (cg-RX-API-DMAC10.html)
JP2009518296A5 (cg-RX-API-DMAC10.html)
JP2012092103A5 (cg-RX-API-DMAC10.html)
RU2013146659A (ru) Способы лечения рака
JP2012512863A5 (cg-RX-API-DMAC10.html)
JP2015507635A5 (cg-RX-API-DMAC10.html)
JP2016528273A5 (cg-RX-API-DMAC10.html)
JP2015500842A5 (cg-RX-API-DMAC10.html)